A 12-Week Treatment with the Long-Acting Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Leads to Significant Weight Loss in a Subset of Obese Women with Newly Diagnosed Polycystic Ovary Syndrome

    January 2015 in “ Hormones ”
    Mojca Jensterle, Nika Aleksandra Kravos, Marija Pfeifer … Andrej Janez
    Studysummary In this study, short-term liraglutide treatment led to significant weight loss in obese women with newly diagnosed PCOS and a higher metabolic risk profile compared to metformin.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on link.springer.com →
    Discuss this study in the Community →

    Research cited in this study 2

    1. Evidence-Based and Potential Benefits of Metformin in Polycystic Ovary Syndrome: A Comprehensive Review Endocrine Reviews · 2008
    2. Ghrelin Levels Are Suppressed and Show a Blunted Response to Oral Glucose in Women with Polycystic Ovary Syndrome European journal of endocrinology · 2008